Renke Guilherme, Callizo Consuelo, Paes Raphaela, Antunes Mariana, Michels Glaycon, Concha Luana, Almeida Ordânio, Valente Christiane, Baesso Thomaz, Giovannoni Bruna
Nutrindo Ideais Performance and Nutrition Research Center, Rio de Janeiro 22411-040, Brazil.
Clementino Fraga Filho University Hospital, Federal University of Rio de Janeiro, Rio de Janeiro 21941-913, Brazil.
Biomedicines. 2023 Sep 21;11(9):2586. doi: 10.3390/biomedicines11092586.
Segesterone acetate (SA) or Nestorone, a fourth-generation progestogen, is a synthetic compound with high progestational activity and no androgenic, glucocorticoid, or anabolic effects. However, due to its oral inactivity, SA must be used by other routes, such as subcutaneous. Thus, considering its peculiar properties, the SA subdermal implant is successfully used in female contraception and postmenopausal hormone replacement therapy (HRT). In recent years, its potential uses in endometriosis, polycystic ovaries syndrome (PCOS), and a new therapeutic possibility for neuroprotection have made this treatment extremely interesting. However, the absence of a standardized dose and the long-term safety of SA implant therapy in women is still controversial. Here, we present the possible indications, doses, limitations, and side effects of SA implant therapy.
醋酸孕二烯酮（SA）或内美通，一种第四代孕激素，是一种具有高孕激素活性且无雄激素、糖皮质激素或合成代谢作用的合成化合物。然而，由于其口服无活性，SA必须通过其他途径使用，如皮下给药。因此，考虑到其特殊性质，SA皮下植入剂已成功用于女性避孕和绝经后激素替代疗法（HRT）。近年来，其在子宫内膜异位症、多囊卵巢综合征（PCOS）中的潜在用途以及神经保护的新治疗可能性使这种治疗极具吸引力。然而，SA植入疗法在女性中的标准化剂量缺失以及长期安全性仍存在争议。在此，我们介绍SA植入疗法的可能适应症、剂量、局限性和副作用。
